Trial Profile
Treatment of Patients With Castration Resistant Prostate Cancer Using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs ETBX- 071 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; First in man
- 28 Apr 2021 Status changed from active, no longer recruiting to completed.
- 29 Mar 2021 According to an ImmunityBio media release, this study undertaken in collaboration with Investigators at the Genitourinary Malignancy Branch of the National Cancer Institute.
- 29 Mar 2021 According to an ImmunityBio media release, data published in the Journal of ImmunoTherapy of Cancer (JITC).